Nippon India Pharma Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹643.59+0.24%
07 Sept 2026
Rolling Returns Analysis
Rolling annualized returns of Nippon India Pharma Fund Direct-Growth across 1Y, 3Y and 5Y windows — average, best, worst returns and percentage of positive return periods.
| Metric | 1 Yr Rolling Returns | 3 Yr Rolling Returns | 5 Yr Rolling Returns | 7 Yr Rolling Returns |
|---|---|---|---|---|
| Analysis period | 07 Jan, 2014 - 07 Sep, 2026 | 22 Jan, 2016 - 07 Sep, 2026 | 01 Feb, 2018 - 07 Sep, 2026 | 13 Feb, 2020 - 07 Sep, 2026 |
| Average returns | 20.67% | 17.43% | 16.94% | 17.40% |
| Standard deviation | 23.74% | 9.02% | 6.21% | 3.88% |
| Best returns | 87.68% 1 year ending on 25 Mar, 2021 | 32.15% 3 years ending on 09 Aug, 2021 | 32.02% 5 years ending on 13 Sep, 2024 | 24.55% 7 years ending on 25 Sep, 2024 |
| Worst returns | -15.46% 1 year ending on 07 Oct, 2019 | -1.61% 3 years ending on 07 Oct, 2019 | 1.21% 5 years ending on 23 Mar, 2020 | 9.52% 7 years ending on 26 Sep, 2022 |
| Period with positive return | 76.43% | 98.97% | 100.00% | 100.00% |
| Period with return > 5% | 65.60% | 80.80% | 97.26% | 100.00% |
| Period with return > 10% | 55.63% | 74.81% | 85.71% | 99.69% |
| Period with return > 15% | 47.84% | 70.88% | 68.07% | 69.94% |
| Beat % Category | 44.76% | 51.03% | 64.76% | 81.60% |
| Beat % Benchmark | 80.51% | 92.71% | 99.25% | 100.00% |
Trailing Returns
Point-to-point returns of Nippon India Pharma Fund Direct-Growth vs category average for YTD, 1M, 6M, 1Y, 3Y, 5Y and 10Y periods — with category rank and total funds count.
0%
10%
20%
30%
40%
12.9%
19.0%
18.1%
YTD
0.3%
0.4%
0.5%
1 M
12.5%
19.3%
16.5%
6 M
12.3%
18.3%
22.7%
1 Y
18.9%
22.8%
47.3%
3 Y
13.8%
15.7%
14.0%
5 Y
15.8%
15.3%
9.4%
10 Y
Fund
Equity: Sectoral-Pharma
BSE Healthcare Total Return Index
| Name | YTD | 1 M | 6 M | 1 Y | 3 Y | 5 Y | 10 Y | Since Inception |
|---|---|---|---|---|---|---|---|---|
| Fund | 12.95% | 0.25% | 12.50% | 12.33% | 18.93% | 13.79% | 15.78% | 17.61% |
| Equity: Sectoral-Pharma | 19.02% | 0.44% | 19.32% | 18.26% | 22.79% | 15.66% | 15.35% | - |
| BSE Healthcare Total Return Index | 18.07% | 0.52% | 16.54% | 22.74% | 47.28% | 13.97% | 9.42% | - |
| Rank in category | 20 | 13 | 21 | 18 | 11 | 7 | 1 | - |
| Funds in category | 22 | 23 | 22 | 21 | 11 | 8 | 4 | - |
Period Returns
Calendar-year, quarterly and monthly return history of Nippon India Pharma Fund Direct-Growth. Toggle between bar chart and table view to analyse periodic performance trends.
Historical Performance
Track NAV movement and cumulative returns of Nippon India Pharma Fund Direct-Growth across 1M, 6M, 1Y, 3Y, 5Y and since-inception periods. Compare SIP and lumpsum growth over time.
Compare performance with respect toAdd benchmark
Add benchmark
Frequently Asked Questions
What are the 1-year returns of Nippon India Pharma Fund Direct-Growth?
Nippon India Pharma Fund Direct-Growth has delivered a 1-year return of 12.33% as of 6 Sep 2026. During the same period, its benchmark BSE Healthcare Total Return Index returned 22.74%. The fund has underperformed its benchmark over this period.
What are the 3-year returns of Nippon India Pharma Fund Direct-Growth?
Nippon India Pharma Fund Direct-Growth has delivered a 3-year CAGR of 18.93% as of 6 Sep 2026. Its benchmark BSE Healthcare Total Return Index returned 47.28% CAGR over the same period. CAGR (Compounded Annual Growth Rate) is the right way to evaluate multi-year mutual fund performance as it smooths out year-to-year volatility.
What are the 5-year returns of Nippon India Pharma Fund Direct-Growth?
Nippon India Pharma Fund Direct-Growth has delivered a 5-year CAGR of 13.79% as of 6 Sep 2026. Its benchmark BSE Healthcare Total Return Index returned 13.97% CAGR over the same period. A 5-year track record is considered a more reliable indicator of fund quality than shorter-term performance, as it captures at least one full market cycle.
What are the returns of Nippon India Pharma Fund Direct-Growth since inception?
Since its launch on 31 Dec 2012, Nippon India Pharma Fund Direct-Growth has delivered a CAGR of 17.61%. Since-inception returns reflect the fund's full history and give the most complete picture of long-term performance.
How has Nippon India Pharma Fund Direct-Growth performed vs its category over the long term?
Over the long term, Nippon India Pharma Fund Direct-Growth has ranked 11 out of 11 funds in the Equity: Sectoral-Pharma category on a 3-year basis, and 7 out of 8 funds on a 5-year basis. Category rank is one of several factors to consider alongside risk metrics and rolling return consistency when evaluating a fund.
What is the Sharpe ratio of Nippon India Pharma Fund Direct-Growth?
The Sharpe ratio of Nippon India Pharma Fund Direct-Growth is 0.92 (as of 6 Sep 2026). The Sharpe ratio measures how much return the fund generates per unit of risk (volatility) taken. A Sharpe ratio above 1.0 is generally considered good — the higher the ratio, the better the risk-adjusted return.
What is the alpha of Nippon India Pharma Fund Direct-Growth?
The 3Y alpha of Nippon India Pharma Fund Direct-Growth is -1.15% (as of 6 Sep 2026). Alpha measures the excess return generated by the fund over and above its benchmark BSE Healthcare Total Return Index, after adjusting for risk. A positive alpha means the fund manager has added value beyond what the market delivered. A negative alpha means the fund has underperformed its benchmark on a risk-adjusted basis.
What is the beta of Nippon India Pharma Fund Direct-Growth?
The beta of Nippon India Pharma Fund Direct-Growth is 0.88 (as of 6 Sep 2026). Beta measures how sensitive the fund is to market movements relative to its benchmark BSE Healthcare Total Return Index. A beta of 1 means the fund moves in line with the market. A beta above 1 means it is more volatile than the market; below 1 means it is less volatile. Nippon India Pharma Fund Direct-Growth's beta of 0.88 indicates it is more defensive than its benchmark.
What are the rolling returns of Nippon India Pharma Fund Direct-Growth?
The average 1-year and 3-year rolling returns of Nippon India Pharma Fund Direct-Growth is 20.67% and 17.43% respectively. Rolling returns show the fund's annualized return across every possible 1-year and 3-year investment window, making them a far more reliable measure of consistency than point-to-point returns, which depend heavily on the start and end date chosen.